Multivariate analysis of TRM and relapse
Variable . | N . | RR . | Lower CL . | Upper CL . | P . |
---|---|---|---|---|---|
TRM, main effect* | |||||
Full intensity | 1428 | 1.00 | |||
RIC | 93 | 0.98 | 0.66 | 1.46 | .92 |
TRM, other significant factors | |||||
Patient age at transplantation, y | |||||
Less than 30 | 821 | 1.00 | Poverall < .001 | ||
30-39 | 330 | 1.49 | 1.19 | 1.86 | .001 |
40-49 | 226 | 1.52 | 1.17 | 1.96 | .002 |
50 or more | 144 | 1.89 | 1.36 | 2.63 | < .001 |
KPS before transplantation | |||||
Less than 80% | 119 | 1.00 | Poverall = .014 | ||
80% or more | 1339 | 0.65 | 0.48 | 0.87 | .005 |
Missing | 63 | 0.79 | 0.48 | 1.32 | .37 |
Disease status before transplantation | |||||
CR1 | 802 | 1.00 | |||
CR2 | 719 | 1.35 | 1.11 | 1.63 | .001 |
Type of donor | |||||
HLA-identical sibling | 617 | 1.00 | Poverall < .001 | ||
Unrelated well matched | 428 | 1.11 | 0.86 | 1.44 | .42 |
Unrelated partially matched | 315 | 1.43 | 1.12 | 1.84 | .005 |
Unrelated mismatched/unknown | 161 | 2.47 | 1.88 | 3.25 | < .001 |
Year of transplantation | |||||
2002-2007 | 784 | 1.00 | |||
1995-2001 | 737 | 1.39 | 1.12 | 1.72 | .003 |
GVHD prophylaxis | |||||
Tacrolimus- or CSA-based ± MTX ± other | 1340 | 1.00 | Poverall = .012 | ||
TCD | 126 | 1.45 | 1.09 | 1.90 | .001 |
Other/none/missing | 55 | 1.03 | 0.61 | 1.76 | .91 |
Relapse, main effect | |||||
Full intensity | 1428 | 1.00 | |||
RIC | 93 | 1.35 | 0.91 | 2.01 | .14 |
Relapse, other significant factors | |||||
KPS before transplantation | |||||
Less than 80% | 119 | 1.00 | .001 | ||
80% or more | 1339 | 0.56 | 0.40 | 0.78 | .001 |
Missing | 63 | 0.83 | 0.48 | 1.43 | .51 |
TBI given for conditioning regimen | |||||
Yes | 1293 | 1.00 | |||
No | 228 | 1.55 | 1.18 | 2.03 | .002 |
Disease status before transplantation | |||||
CR1 | 802 | 1.00 | Poverall < .001 | ||
CR2, CR1 duration < 12 mo | 224 | 2.75 | 2.12 | 3.57 | < .001 |
CR2, CR1 duration ≥ 12 mo | 391 | 1.51 | 1.18 | 1.93 | .001 |
CR2, CR1 duration missing | 104 | 1.29 | 0.85 | 1.97 | .23 |
Variable . | N . | RR . | Lower CL . | Upper CL . | P . |
---|---|---|---|---|---|
TRM, main effect* | |||||
Full intensity | 1428 | 1.00 | |||
RIC | 93 | 0.98 | 0.66 | 1.46 | .92 |
TRM, other significant factors | |||||
Patient age at transplantation, y | |||||
Less than 30 | 821 | 1.00 | Poverall < .001 | ||
30-39 | 330 | 1.49 | 1.19 | 1.86 | .001 |
40-49 | 226 | 1.52 | 1.17 | 1.96 | .002 |
50 or more | 144 | 1.89 | 1.36 | 2.63 | < .001 |
KPS before transplantation | |||||
Less than 80% | 119 | 1.00 | Poverall = .014 | ||
80% or more | 1339 | 0.65 | 0.48 | 0.87 | .005 |
Missing | 63 | 0.79 | 0.48 | 1.32 | .37 |
Disease status before transplantation | |||||
CR1 | 802 | 1.00 | |||
CR2 | 719 | 1.35 | 1.11 | 1.63 | .001 |
Type of donor | |||||
HLA-identical sibling | 617 | 1.00 | Poverall < .001 | ||
Unrelated well matched | 428 | 1.11 | 0.86 | 1.44 | .42 |
Unrelated partially matched | 315 | 1.43 | 1.12 | 1.84 | .005 |
Unrelated mismatched/unknown | 161 | 2.47 | 1.88 | 3.25 | < .001 |
Year of transplantation | |||||
2002-2007 | 784 | 1.00 | |||
1995-2001 | 737 | 1.39 | 1.12 | 1.72 | .003 |
GVHD prophylaxis | |||||
Tacrolimus- or CSA-based ± MTX ± other | 1340 | 1.00 | Poverall = .012 | ||
TCD | 126 | 1.45 | 1.09 | 1.90 | .001 |
Other/none/missing | 55 | 1.03 | 0.61 | 1.76 | .91 |
Relapse, main effect | |||||
Full intensity | 1428 | 1.00 | |||
RIC | 93 | 1.35 | 0.91 | 2.01 | .14 |
Relapse, other significant factors | |||||
KPS before transplantation | |||||
Less than 80% | 119 | 1.00 | .001 | ||
80% or more | 1339 | 0.56 | 0.40 | 0.78 | .001 |
Missing | 63 | 0.83 | 0.48 | 1.43 | .51 |
TBI given for conditioning regimen | |||||
Yes | 1293 | 1.00 | |||
No | 228 | 1.55 | 1.18 | 2.03 | .002 |
Disease status before transplantation | |||||
CR1 | 802 | 1.00 | Poverall < .001 | ||
CR2, CR1 duration < 12 mo | 224 | 2.75 | 2.12 | 3.57 | < .001 |
CR2, CR1 duration ≥ 12 mo | 391 | 1.51 | 1.18 | 1.93 | .001 |
CR2, CR1 duration missing | 104 | 1.29 | 0.85 | 1.97 | .23 |
CL indicates confidence limit.
Stratified variable: graft type.